CytoKi Pharma raises 45M USD series A

CytoKi closes $45M series A to harness IL-22 signaling for epithelial repair.

CytoKi Pharma today announced a $45 million series A financing led by existing investor Lundbeckfonden Emerge (Denmark) together with Seventure Partners (France), +ND Capital (Switzerland) and Ysios Capital (Spain). The series A will support the development of its lead program (lipidated IL-22) through clinical proof of concept in Inflammatory Bowel Disease and explore expansion in additional pathologies related to epithelial tissue injury.

Read full press release